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Background and purpose: Topiramate (TPM) is a sulfa-derivative monosaccharide that is 
used mainly for treating epilepsy and preventing migraine. Within the gamut of side effects 
attributable to this drug, ophthalmologic manifestations are of crucial importance. In this study, 
for the first time, the aim was to provide a systematic literature review regarding this issue.
Methods: For the time period 1996–2011, a PubMed search was made for the studies concerning 
the adverse/beneficial effects of TPM on vision. Overall, 404 citations out of a total of 2756 
TPM-related studies were examined for relevance.
Results: A total of 74 relevant studies were reviewed, 65 of which comprise small   observational 
studies describing the ophthalmic side effects of TPM in 84 patients. Of these patients, 66 were 
affected by ciliochoroidal effusion syndrome as the cardinal ocular side effect of TPM (17 cases 
of myopic shift and 49 cases of angle closure glaucoma). A comprehensive statistical an  alysis is 
provided on these 66 subjects. Other rare side effects of TPM on the vision were also reviewed, 
including massive choroidal effusion, ocular inflammatory reactions, visual field defects, 
  probable effects on retina, cornea, and sclera, and neuroophthalmologic complications. In 
addition, a framework is provided to classify these results.
Discussion: Due to the expanding spectrum of indications for the administration of TPM, 
neurologists and psychiatrists should be aware of its diverse ocular side effects. In conclusion, 
ocular complications following this drug should be taken seriously and be subjected to   ophthalmic 
counseling.
Keywords: topiramate, eye, vision, ophthalmology, side effect, review
Introduction
Topiramate (TPM) is a sulfa-derivative monosaccharide with several mechanisms of 
action, including blockage of voltage-gated sodium channels, hyperpolarization of 
potassium currents, enhancement of postsynaptic gamma-aminobutyric acid   receptor 
activity, suppression of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA)/kainite receptor, and mild inhibition of some carbonic anhydrase isoen-
zymes.1–4 This drug is rapidly absorbed after oral intake, crosses the blood-brain 
barrier,5 and is generally excreted in urine with an elimination half-life of almost 
24 hours.6
Originally, the reputation of TPM emerged from its anticonvulsant properties. 
In 1996, it was approved by the Food and Drug Administration for the treatment of 
epilepsy and was found to be effective when applied as a monotherapy for tonic–clonic 
and partial seizures with or without generalization. Also, as an adjunctive drug, it 
was efficacious in controlling seizures associated with Lennox–Gastaut syndrome.4,7 
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Later, in 2004, the Food and Drug Administration further 
approved the use of TPM for migraine prevention.8 Since 
then, a wide spectrum of other indications for its use has 
been suggested in the literature, including infantile spasms,9 
  bipolar disorder,10 posttraumatic stress disorder,11 obe-
sity,12 alcohol dependence,13 eating disorders,14 obsessive-
  compulsive disorder,15 idiopathic intracranial hypertension,16 
neuropathic pain,17 tobacco dependence,18 essential tremor,19 
postherpetic neuralgia,20 and Tourette’s disorder.21
Nowadays, with the broadening of the spectrum of uses 
for TPM, the range of diverse adverse effects of the drug 
is increasing. Of note, the most common systemic adverse 
effects are somnolence, psychomotor slowing, fatigue, 
  cognitive disorders, and nephrolithiasis.3 Moreover, in cases 
of acute overdose, vertigo, agitation, mydriasis, generalized 
seizure, and metabolic acidosis have been documented.22 In 
particular, ophthalmologic side effects, due to their variety 
and severity, are of primary importance.2 Therefore, it is 
crucial for neurologists, psychiatrists, and ophthalmologists 
to be aware of these risks.
To our knowledge, there is no comprehensive review 
consolidating the results of previous studies on this subject. 
For this reason, our aim was to gather data that will provide 
useful guidelines for practitioners dealing with the possible 
ophthalmic adverse side effects of TPM. Furthermore, 
sparse beneficial effects of this drug on a patient’s vision are 
reviewed. In this study, we present a large body of results from 
previously published works analyze their data from a holistic 
view, provide a framework within which they can be classi-
fied, and suggest possible conclusions and solutions.
Methods
Search strategy and citations library
In order to collect material for this study, a detailed search 
in PubMed database was performed using EndNote® version 
X5 software (Thomson Reuters, Carlsbad, CA) for the time 
period from 1996 (date of TPM approval) until August 2011. 
Firstly, a library was built which included all studies that 
contained the term “topiramate,” resulting in 2756 items. 
Then, this library was searched for any term related to 
ophthalmology. The terms (results count) were as follows: 
“eye” (67), “vision” (190), “visual” (110), “ophthalm-” (61), 
“ocul-” (56), “optic” (18), “globe” (0), “lens” (14), “retina” 
(33), “angle” (69), “uveitis” (4), “uvea” (16), “choroid” (19), 
“cilia” (25), “cilio-” (14), “refraction” (4), “refractive” (7), 
“myop-” (39), “glaucoma” (77), “cornea” (17), “sclera” 
(3), and “scleritis” (3). These results were filed separately 
and then merged together into another library comprising 
846 items. Removal of duplicates yielded a total of 404 
citations.
Inclusion and exclusion criteria
All titles/abstracts of articles without any language   restriction 
were studied concurrently for relevance by two authors (MAA 
and SHA). Firstly, review articles were excluded. The criteria 
for including specific study designs were: any controlled 
or noncontrolled trial, prospective cohort, experimental 
intervention, case-control, cross-sectional, case report/
series studies, and letters/correspondences. Subsequently, 
after meticulous scrutiny, the results were narrowed down 
to 74 articles   relevant to the effects of TPM on vision, both 
beneficial and adverse. The full text of eligible works, written 
in English, French, German, Portuguese, and Spanish was 
obtained and studied. However, only the English abstracts of 
the articles in other languages (ie, one in Japanese and one in 
Hebrew) were considered. Eligible subjects were examined 
for direct relevance to one of the following topics: (a) TPM 
visual side effects in a single subject, or in a group of subjects, 
reported in either observational or interventional studies, or 
(b) direct therapeutic applications of TPM in ophthalmology 
and allied sciences (eg, neuroophthalmology) in both trial 
and experimental fields.
Article classifications
Overall, based on topic and method of eligible studies in 
their data collection, articles were assigned to the following 
categories: (a) studies extracted from the records of the World 
Health Organization or other related/similar organizations 
concerning drug safety, (b) prospective studies concerning 
the adverse ophthalmic effects of TPM, (c) experimental 
studies concerning possible positive/negative effects of 
TPM on vision, (d) studies reporting beneficial effects of 
TPM on vision limited to a small number of human cases, 
and (e) short studies that reported a single case or cases 
with exceptional complications associated with TPM on a 
cohort of consumers. These studies included original/brief 
communications, case reports/series, letters to the editor, 
and correspondences.
Further data extraction and statistical 
analysis
Data of the cases pertaining to category “e” (as mentioned 
above) were further extracted and summarized based on 
the following items: chief complaint and manifestations, 
sex, age, TPM indication, dosage (mg/day), and duration of 
administration, values of intraocular pressure (IOP; mmHg) 
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and myopic shift (MS; diopters) when available, significant 
ocular examinations and laboratory datum, recovery period, 
and therapeutic procedures. Also, patients of this   category 
were further classified into three main groups: cases 
  complicated with (a) TPM-induced angle closure glaucoma 
(TiACG), (b) TPM-induced MS (TiMS), and (c) other TPM-
induced ophthalmic defects.
Next, detailed statistical analyses were performed on 
patients in groups TiACG and TiMS. The variables   analyzed 
in each group were as follows: (a) sex ratio, (b) TPM 
indications, (c) age (years), (d) TPM dosage (mg/day), 
(e) duration of TPM administration, (f) IOP and/or MS (in 
right eye [OD], left eye [OS], and both eyes [OU; mean value 
of OD and OS]). Based on the quality of any variable, results 
were reported as mean ± standard deviation, mode, median, 
and/or number (percent).
In order to compare two eyes for their difference in IOP 
or MS, Wilcoxon signed-rank test or a paired sample t-test 
was employed. For small samples (ie, n , 5),   Mann–Whitney 
U test was used. In addition, in order to examine the 
  correlation of TPM dosage with the values of IOP (OU) or 
MS (OU), Spearman’s rank test was applied. Data   analyses 
were   carried out by IBM SPSS version 19.0 software 
(SPSS, Inc, Chicago, IL) and P , 0.05 was considered the 
significance threshold.
Results
Article classifications
Among 74 included studies: (a) two studies were c  arried 
out using general health organizations’ documents (eg, 
World Health Organization),23,24 (b) two were prospective 
cohort studies c  oncerning the adverse ophthalmic effects of 
TPM,25,26 (c) three were experimental studies concerning pos-
sible positive/negative effects of TPM on vision,27–29(d) two 
were case reports describing the possible beneficial effects 
of TPM on vision,30,31 and (e) 65 were small observational 
studies that described the ophthalmic side effects of TPM 
in consumers.32–96
Extracted/analyzed data
Overall, in the category “e” studies, a total of 84 patients 
were described; demographic, clinical, and paraclinical 
details are reviewed and summarized in Table 1. Patients 
described in this table can be classified into three main 
groups: cases co  mplicated with (a) TiMS (17 patients), 
(b) TiACG (49 patients), and (c) other TPM-induced oph-
thalmic side effects (18 patients). Data of the 66 patients 
in the TiMS and TiACG groups are further analyzed 
in Table 2. In addition to demographic data, TPM-related 
data (administration   duration, indication, and dosage) and 
paraclinical data (MS and IOP values) are analyzed both 
qualitatively and   quantitatively. Other analyses include tests 
for comparing two eyes for IOP or MS values that showed no 
statistically significant difference. Moreover, the correlation 
of TPM dosage with either MS (OU) or IOP (OU) was exam-
ined, and it showed no significant relationship (Table 2).
TPM ophthalmologic complications
Ciliochoroidal effusion syndrome
Definition and spectrum of ciliochoroidal effusion 
syndrome
The best known and most common ophthalmic   complication 
of TPM is acute onset of ciliochoroidal effusion syndrome. 
Ciliochoroidal effusion syndrome can be defined as a 
  spectrum of clinical manifestations ranging from transient 
TiMS to severe bilateral TiACG.
On one hand, transient TiMS causes acute   transitory 
blurred vision that spontaneously resolves after drug 
  cessation.32 On the other hand, TiACG can be refractory 
to ordinary ocular hypotensive drugs (whether topical or 
systemic), leading to ocular complications such as cataract, 
uveitis, and even permanent visual loss.61,89 The origin of 
the term “ciliochoroidal effusion syndrome” emerged in 
2002 when ophthalmologists were trying to explain the 
pathomechanism of TiMS and TiACG.97 The history of this 
issue will be discussed under the next subheading.
Overall, ciliochoroidal effusion syndrome can occur 
days or weeks after drug administration (Table 2). Also, 
there are documented patients in whom symptoms occurred 
within a few days or weeks after doubling of the drug 
dosage.54,65,69,77,79,92 According to a Food and Drug Admin-
istration report, the prevalence of ciliochoroidal effusion 
syndrome is three per 100,000 of all TPM consumers.4 
However, some authors believe that this rate might be an 
underestimation.88   According to the present review, 50 (75%) 
of the 66 patients were female. This female preponderance 
might be due to the predominance of females taking TPM, 
since approximately 70% of TPM consumers are women 
(corporate data on file at Ortho-McNeil).
Suggested mechanisms for TiACG and TiMS and the 
origin of the term “ciliochoroidal effusion syndrome”
In 2001, Banta et al34 reported the first case of acute bilateral 
uveal effusion and TiACG in a 51-year-old man. Thereafter, 
this condition was frequently reported (over 100 confirmed 
cases).23 As mentioned, TPM is a sulfa-derivative drug. It is 
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now well documented that other sulfa derivatives such as 
sulfamethizole, chlortalidone, ethoxzolamide, hydrochloro-
thiazide, sulfapyridine, trimethoprim, and acetazolamide can 
induce MS and ACG.2 The exact mechanism by which TPM 
and other sulfa derivatives initially triggers TiACG and TiMS 
is not completely understood.23 However, to date, a number 
of mechanisms have been suggested as possible triggers.
One of the earliest hypotheses was proposed by Sen 
et al.33 They suggested that the entry of TPM into the lens 
alters its osmotic status, causing it to swell and, consequently, 
resulting in TiACG and TiMS. Later in 2004, Craig et al46 
reported two patients with acute myopia on whom they 
performed detailed angle evaluations. They challenged the 
theory of Sen et al by stating that changes in the thickness of 
the lens would not be significant enough to be the only cause 
of MS. In their observations, lens swelling accounted for only 
9%–16% of the decrease of anterior chamber depth.
Another hypothesis originated from two separate studies 
concerning the side effects of TPM conducted in 2001, in 
which two cases of uveal effusion36 and one case of ciliary 
swelling35 were described. In the following year, in response 
to these reports, Ikeda et al97 introduced a new clinical term, 
namely “ciliochoroidal effusion syndrome,” to describe the 
disorders induced by the administration of sulfa derivatives. 
They proposed a new mechanism to explain such phenomena 
and suggested that TPM-related ocular signs and symptoms 
were similar to those induced by other sulfa derivatives, eg, 
acetazolamide and hydrochlorothiazide. These complications 
were attributed to ciliochoroidal effusion and swelling of the 
ciliary body, which can potentially result in anterior rotation of 
the ciliary processes, causing narrowing of the ciliary sulcus 
and forward displacement of the iris. These events might lead 
to forward movement of the lens towards the iris diaphragm, 
and, consequently, induce ACG. Furthermore, ciliary body 
swelling could result in relaxation of the lens zonules causing 
lens thickening and the development of myopia.97
TiACG is suggested to have an underlying inflammatory 
component. In the literature, this is supported by: (a) a case 
of anterior uveitis and another case of vitritis associated 
with TiACG,56,89 and (b) three cases of refractory TiACG 
that responded dramatically to high doses of intravenous 
methylprednisolone.54,77,92
Ciliochoroidal effusion syndrome is probably due to 
idiosyncratic reactions. In the literature, there are three main 
supporting pieces of evidence for this preposition. Firstly, 
these complications occur in a small proportion of patients 
taking this drug,4 which points towards the idiosyncrasy 
hypothesis. Secondly, there is a report of TiACG in which the 
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Table 2 Qualitative and quantitative analysis on demographic, clinical, and paraclinical data of 66 patients with topiramate visual side 
effects including angle closure glaucoma (49 cases) and myopic shift (17 cases)
Ciliochoroidal effusion syndrome patients 
(N = 66) (F:M = 50:16)
TiACG patients 
(N = 49) (F:M = 36:13)
TiMS patients 
(N = 17) (F:M = 14:3)
Age (year) 
  ,40 years old 
  $40 years old
  Duration of TPM administration to symptoms (days) 
  First week 
  Second week 
  Third week 
  Fourth week 
  .4 weeks
39.08 ± 13.89 [5, 68, 23, 39.5] (n = 48) 
24 (50%) 
24 (50%)
12.38 ± 10.80 [1, 60, 7, 10] (n = 47) 
21 (45%) 
18 (38%) 
3 (6%) 
0 (0%) 
5 (11%)
32 ± 9.80 [15, 45, 40, 34] (n = 17) 
11 (65%) 
6 (35%)
8.59 ± 7.24 [1, 30, 1, 8] (n = 17) 
8 (47%) 
6 (35%) 
2 (12%) 
0 (0%) 
1 (6%)
TPM indication 
  Migraine and other headaches 
  Seizure 
  Psychological issues 
  Pain 
  Alcohol addiction 
  Overweight
(n = 46) 
28 (61%) 
6 (13%) 
6 (13%) 
3 (7%) 
2 (4%) 
1 (2%)
(n = 16) 
7 (44%) 
4 (25%) 
2 (12%) 
0 (0%) 
0 (0%) 
3 (19%)
TPM dosage (mg/day) 
  25 
  50 
  75 
  100 
  150
53.57 ± 33.13 [25, 150, 25, 50] (n = 28) 
11 (39%) 
10 (36%) 
1 (3.5%) 
5 (18%) 
1 (3.5%)
51.56 ± 26.56 [25, 100, 50, 50] (n = 16) 
5 (31%) 
8 (50%) 
0 (0%) 
3 (19%) 
0 (0%)
MS (OU) 5.66 ± 1.57 [2.75, 8.5, 5, 5.25] (n = 19) 5.34 ± 1.85 [2.62, 8.5, 4, 5.75] (n = 11)
Correlation of TPM dosage with MS (OU) values P = 0.5433, P = -0.183¶ 
[95% CI: -0.685 to 0.437] (n = 12)
P = 0.4822, P = -0.234¶  
[95% CI: -0.753 to 0.464] (n = 10)
MS (OD) 5.85 ± 2.06 [2, 10, 5, 5.25] (n = 20) 5.32 ± 1.87 [2.5, 8, 8, 5] (n = 11)
MS (OS) 5.49 ± 1.27 [3.5, 7.5, 6, 5.25] (n = 19) 5.36 ± 1.90 [2.75, 9, 6.5, 5.5] (n = 11)
Difference of MS values between two eyes P = 0.2324 (n = 19)‡ P = 1.0000 (n = 11)‡
IOP (OU) 47.15 ± 15.16 [24, 85, 48, 44.25] (n = 46) 18.87 ± 1.43 [18, 21, 18, 18.25] (n = 4)
Correlation of TPM dosage with IOP (OU) values P = 0.1015, P = 0.328¶  
[95% CI: -0.0685 to 0.634] (n = 26)
P = 0.1025, P = -0.943¶  
[95% CI: -0.999 to 0.195] (n = 4)
IOP (OD) 47.39 ± 15.36 [24, 88, 40, 45] (n = 46) 19 ± 2 [18, 22, 18, 18] (n = 4)
IOP (OS) 46.91 ± 15.32 [24, 82, 45, 44.5] (n = 46) 18.75 ± 0.96 [18, 20, 18, 18.5] (n = 4)
IOP (OU) ,40 17 (37%) 4 (100%)
IOP (OU) $40 29 (63%) 0 (0%)
Difference of IOP values between two eyes ,5 mmHg 36 (78%) 4 (100%)
Difference of IOP values between two eyes .5 mmHg 10 (22%) 0 (0%)
Difference of IOP values between two eyes P = 0.4891 (n = 46)† P = 0.8857 (n = 4)*
Notes: Data presented as number (percent) or mean ± standard deviation [lower range, upper range, mode, median]. The number of available specimens in each calculation 
is in parentheses (n). Statistical tests: †paired sample t-test; ‡Wilcoxon signed-rank test; ¶Spearman’s rank test; *Mann–Whitney U test.
Abbreviations: CI, confidence interval; F, female; IOP, intraocular pressure (mmHg), M, male; MS, myopic shift (diopters); OD, right eye; OS, left eye; OU, both eyes (mean 
value of right eye and left eye), TiACG, topiramate-induced angle closure glaucoma; TiMS, topiramate-induced myopic shift; TPM, topiramate.
plasma level of the drug was lower than the therapeutic level.82 
TiACG is even reported in patients taking low doses of the 
drug (ie, 25 mg/day), which might indicate the in  dependence 
of the severity of symptoms from the do  sage and the idio-
syncratic nature of these complications.85,91 Thirdly, there 
are some instances of severe TPM into  xications without the 
occurrence of ACG.22 In addition to these three points, it is 
worth noting that in the present analysis on the correlation 
of TPM dosage with the level of IOP or MS (Table 2), no 
significant results were obtained in either the TiMS or TiACG 
group. This finding is mostly suggestive of idiosyncrasy. 
However, in a number of calculations the sample size was 
small. Consequently, low statistical power might fail to find 
any significant relationship.
Generally, rechallenge test can be considered as a good 
method to figure out the possible underlying mechanism of 
a drug’s adverse effects. However, there are limited studies 
concerning rechallenge tests on TPM’s ocular side effects 
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and existing reports show controversial results. In a single 
study, three cases of TPM-induced ciliochoroidal effusion 
syndrome were reported with a positive rechallenge test.23 
On the contrary, another study reported no recurrence of 
complications after drug readministration. Notably, in this 
report, lower dosages of the drug were readministered after 
5 days.32
TiMS
TiMS can occur as a solitary clinical manifestation 
of ciliochoroidal effusion syndrome or it can acco-
mpany TiACG. Patients with TiMS often complain of sud-
den blurred vision.38,40 B-scan ultrasonography may show 
uveal effusion,79 and ultrasound biomicroscopy may show 
c  iliochoroidal effusion.93 In the management of TiMS, the 
most important measure is to discontinue TPM and seek an 
alternative agent. The process of drug replacement neces-
sitates direct contact with the physician responsible for the 
original prescription. In isolated TiMS with normal IOP, the 
status of the angle may narrow critically, so it is important to 
monitor ocular status and IOP over the first few days of TPM 
withdrawal.51
TiACG
Generally, ACG is a rare complication in the white population 
under the age of 40 years. However, 50% of the reviewed 
TiACG subjects were younger than 40 years old (Table 2). 
Thus, TiACG might be eligible for consideration as one of 
the leading causes of bilateral ACG in patients under 40 years 
of age.24,74 This complication, when compared with TiMS, 
is more severe and generally includes myopia accompanied 
by other complications. The most common presenting 
  symptom is sudden bilateral blurred vision.23 Other symptoms 
include headache, bilateral ocular pain, transient vision loss, 
  nausea, ocular “pressure sensation,” and vomiting.24 It is to 
be noted that in patients for whom TPM is administered as 
a migraine therapy, TiACG-associated headaches might be 
misdiagnosed as a migraine attack.69 In a patient with previ-
ous history of migraine, the initial symptom of TiACG was 
left-sided headache with blurred vision and haloes around 
lights. Symptoms rapidly progressed to involve the right side. 
TiACG was misdiagnosed as an acute attack of migraine and 
the patient was treated with intravenous morphine and higher 
doses of TPM, which apparently aggravated the problem.92 
Thus, it is important to differentiate TPM-associated visual 
disturbances from migraine visual aura.77
In 2004, Fraunfelder et al23 gathered all available 
86 reports related to TiACG. Among these cases, three had 
unilateral presentation. However, in the present review of 49 
cases (Table 2), TiACG was bilateral in all and the IOP differ-
ence between the two eyes was ,5 mmHg in 78% of patients. 
Also, mean (± standard deviation) IOP was not statistically 
different between the two eyes. In contrast to the report 
by Van Issum et al,88 in which they suggested that TiACG 
is frequently associated with an IOP ,40 mmHg. In the 
present review, it was found that IOP (OU) was $40 mmHg 
in about 63% of patients.
In the study by Fraunfelder et al, age at the adverse event 
ranged 3–70 years (mean: 34 years). The dosage of TPM 
varied highly among patients: 50 mg/day or less in 47%, 
50–75 mg/day in 33%, 100 mg/day in 13%, and .100 mg in 
7% of cases. Symptoms occurred within a mean duration of 
7 days after initiation of treatment (range 1–49 days). In 85% 
of cases, adverse effects presented within the first 2 weeks of 
TPM administration and in a number of cases IOP exceeded 
70 mmHg. Seven cases developed permanent vision loss after 
the resolution of symptoms.23
Was ciliochoroidal effusion syndrome observed  
in prospective studies on TPM consumers?
In 2009, Leung et al26 published the results of the first 
prospective study evaluating the ophthalmic complications 
of TPM. They studied the effects of short-term (4 weeks) 
TPM administration on angle narrowing in 20 Chinese 
patients aged 18–75 years using ultrasound biomicroscopy. 
They did not observe any significant changes in visual 
acuity, angle parameters, anterior chamber depth, or IOP 
following TPM use. Therefore, they suggested that TPM-
associated angle narrowing might be idiosyncratic, or that 
a period of 4 weeks is too short to induce such phenomena. 
However, in 85% of cases reported by Fraunfelder et al,23 as 
stated earlier, symptoms occurred within the first 2 weeks 
after drug initiation; thus, the period of 4 weeks would have 
been appropriate to detect these ophthalmic complications. 
In this respect, the idiosyncrasy hypothesis appeared to 
be more   conclusive. In 2011, Ozturk et al,25 in a prospec-
tive study on 76 eyes, observed mild MS (median refrac-
tive error increased from -0.25 diopters to -0.62 diopters, 
P , 0.001) within 3 months of follow up. However, no 
significant changes in anterior chamber volume, depth, and 
angle were detected.
Imaging techniques in TiACG
Ultrasound biomicroscopy is one of the best methods to 
confirm the diagnosis of acute ACG. This imaging technique 
can provide a detailed evaluation of angle parameters and 
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detect evidence of ciliochoroidal effusion.26,40,41,53–56,68,81,84 
B-scan ultrasonography helps to detect posterior choroidal 
detachment which is usually shallow,34,42,46,51–54,66,69,89 but may 
sometimes be large and extend to the posterior pole.92
Another useful technique is ocular coherence tomography 
of the anterior segment.86 Some authors used serial anterior 
segment ocular coherence tomography to evaluate and 
  follow the status of angle closure60,81,86 or to detect anterior 
ciliochoroidal effusion and anterior rotation of the ciliary 
body in TiACG.88 Contrary to ultrasound biomicroscopy, 
ocular coherence tomography is a noncontact method. 
Although ocular coherence tomography can show ciliary 
body effusion, it has limitations in imaging the normal 
heavily pigmented ciliary body.88 Furthermore, the   Pentacam® 
Scheimpflug imaging system (OCULUS, Inc, Lynnwood, 
WA) is an anterior segment imaging modality which was 
used to evaluate angle parameters and corneal thickness in 
two studies, including a prospective cohort.25,83
Management of TiACG
In most cases of TiACG, symptoms resolved soon after 
cessation of the drug. Topical timolol, dorzolamide, 
brimonidine, and oral or intravenous acetazolamide were 
found to be the most suitable ocular hypotensive drugs 
following the discontinuation of TPM.88
In spite of the fact that acetazolamide (oral or intra-
venous) is documented to be successful in reducing the 
IOP of TiACG patients in several reports,41,44,53,66,70 some 
authors argued against its prescription, since it is another 
sulfa-derivative drug similar to TPM.77,79,88 It is worth not-
ing that there are reports indicating that acetazolamide can 
evoke side effects similar to those produced by TPM, such 
as ACG.98
There are several lines of evidence indicating that 
cycloplegics are effective in reducing IOP since they cause 
retraction of the ciliary processes.88 In a patient with bilateral 
TiACG, after 24 hours of right-sided atropine administration, 
deeper anterior chamber (grade IV) was observed OD in 
  comparison with OS (grade II). Nevertheless, over the follow-
up duration, IOP was within normal limits OU.41
Hyperosmotic agents (eg, intravenous mannitol) can also 
be considered to reduce IOP in TiACG patients.54
Pilocarpine and other miotic drugs should be avoided due 
to their adverse effects on angle status and clinical symptoms. 
In some reports, pilocarpine was used before the confirma-
tion of TiACG diagnosis. However, it was discontinued after 
the suspicion of ACG emerged by history taking and angle 
evaluation via ultrasound biomicroscopy or other imaging 
modalities.61,65,67 In a report of severe TiACG, in which the 
patient was refractory to routine hypotensive drugs, the authors 
suggested that primary administration of pilocarpine (2%) by 
another physician had aggravated angle status by causing for-
ward rotation of the ciliary body along with inflammation.61
Topical steroids (eg, prednisolone) had been used in 
numerous studies because many authors believe that an 
inflammatory component exists in TiACG.34,49,53,58,68,77 In 
addition, systemic oral corticosteroids had been used in some 
cases.63 Such an approach has been suggested to facilitate the 
resolution of symptoms.54
Laser iridotomy was performed in some complicated 
cases of TiACG; however, its usefulness is not clear since 
the chief mechanism of TiACG is not pupillary block.88 In 
a report by Fraunfelder et al, physicians were compelled to 
use laser or surgical iridectomy in 21 cases.23
In one study, authors presented a 53-year-old man with 
bilateral ACG who had been taking TPM for 6 weeks. They 
had been unable to categorically differentiate primary ACG 
from TiACG. They had performed laser peripheral iridotomy 
to rule out primary ACG. Thus, it seems that application 
of peripheral iridotomy in TiACG is confined to ruling out 
primary ACG.67
Therapeutic options for refractory TiACG cases
Corticosteroid
Rhee et al54 in 2006 presented their experience with a single 
TiACG patient in whom topical ocular hypotensive drugs, 
topical prednisolone, atropine, and intravenous mannitol 
had failed to reduce very high IOP (exceeding 80 mmHg 
before treatment and more than 70 mmHg after treatment). 
  Administration of intravenous methylprednisolone (250 mg 
every 6 hours) was able to control IOP within 16 hours. 
Authors stated that this reduction could not be attributable 
to mannitol alone as the index case had not received man-
nitol for about 8 hours and this drug has a short half-life 
(2–4 hours). They suggested that the patient’s rapid response 
to corticosteroid could be explained by the existence of an 
inflammatory   mechanism in TiACG. In two other similar 
cases, refractory to routine topical and systemic medica-
tions, the same approach was chosen (ie, methylpredni-
solone 250 mg every 6 hours). Very interestingly, TiACG 
resolved rapidly in both cases following administration of 
methylprednisolone.77,92
Laser therapy
Zalta and Smith,74 in an uncontrolled interventional case 
series, presented four female patients with TiACG who were 
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unresponsive to topical and systemic hypotensives. Argon laser 
peripheral iridoplasty (ALPI) was performed and resulted in 
remarkable decreases in IOP and increases in anterior chamber 
depth OU. In this procedure, a 300- or 500-µm spot size laser 
beam for 0.5 seconds at 200–400 mW was employed. The 
number of laser spots applied in each eye ranged from 36 to 52. 
A few hours after the procedure, they also performed laser 
peripheral iridotomy in all eyes to prevent angle closure. As a 
conclusion, authors proposed that refractory TiACG is eligible 
to be added as a new indication for ALPI. In another report, 
a case of TiACG was treated with ALPI. In less than an hour 
after the procedure, the opening of the angle was remarkable.81 
However, Van Issum et al88 noted that use of ALPI may not 
be indicated in all TiACG cases for two main reasons: firstly, 
because of the common presence of spontaneous resolu-
tion in acute attacks and secondly, because of the additional 
risk of cataract and inflammation induced by ALPI.
Choroidal drainage
In a study on a refractory TiACG case with unilateral 
lenticulocorneal touch, choroidal drainage was carried 
out. However, this is the only instance of TPM-associated 
lenticulocorneal attachment in the literature, and perhaps 
the selection of such an aggressive approach would not be 
appropriate in regular cases of TiACG.61
Trabeculectomy
As far as we are aware, trabeculectomy has never been 
reported to have been performed. However, Van Issum et al88 
suggested its application after the resolution of ciliochoroidal 
effusion to treat refractory glaucoma due to compromised 
angles with peripheral anterior synechia.
TPM-induced massive choroidal effusion
In the majority of choroidal effusion syndrome patients, 
shallow choroidal effusion extends anteriorly to the ciliary 
body.69 It should be mentioned that in the Fraunfelder et al 
study, nine cases of suprachoroidal effusion were ascribed 
to TPM administration.23 Moreover, in another study, 
a 39-year-old male was reported with TiACG and TiMS 
in whom B-scan ultrasonography demonstrated moderate 
choroidal effusion extending to the posterior pole OU.92
In a recent report (co-authored by M-AA, S-HA and 
ME), a 79-year-old male with bilateral 360 degree mas-
sive choroidal detachment after 14 days of TPM 50 mg/day 
administration was described. The patient had neither MS 
nor elevated IOP and recovered within 7 days following 
discontinuation of the drug.96
We compared this case to a similar patient   reportedly 
presenting with choroidal detachment following the 
administration of dorzolamide, another sulfa derivative and 
also a carbonic anhydrase inhibitor. Both cases had uneventful 
cataract surgery in their past history and normal IOP.96,98
TPM-induced ocular inflammatory 
reactions
Uveitis and hypopyon
Jabbarpoor Bonyadi et al89 reported a 40-year-old female 
with TiMS and TiACG who developed bilateral anterior 
uveitis and hypopyon after the control of a glaucoma attack. 
Systemic examination for other causes had negative results. 
Uveitis was controlled with 1 mg/kg oral prednisolone; 
however, the patient eventually developed cataract and 
posterior synechiae. She underwent successful cataract 
surgery 6 months later. The authors suggested that TPM 
should be included as a differential diagnosis of uveitis and 
hypopyon.
Nongranulomatous anterior uveitis
In an Indian report, a 49-year-old male presented with 
bilateral nongranulomatous anterior uveitis with grade IV 
cells and fine keratic precipitates 24 hours after control of a 
TiACG attack.84 The uveitis was controlled with topical and 
systemic corticosteroids.
Conjunctivitis, areflexic mydriasis, and vitritis
Viet Tran et al56 reported a 57-year-old male under TPM 
treatment for bipolar disorder who developed bilateral 
conjunctivitis, areflexic mydriasis, MS, and shallowing of the 
anterior chamber. Severe vitritis was also seen in this case. 
Cerebrospinal fluid analysis showed an increased protein 
content (1581 mg/L) that was in accordance with blood  -
brain barrier rupture. Symptoms subsided within 1 week of 
drug cessation; however, iris atrophy remained as the only 
residual complication.
Retinal side effects
Ozturk et al25 investigated changes of retina and retinal nerve 
fiber layer thickness associated with TPM in a prospective 
study. In a follow-up period of 3 months, no statistically 
significant change was seen in retinal thickness. However, 
retinal nerve fiber layer thickness was significantly increased 
(P = 0.004).
In an experimental study, Kjellstrom et al29 evaluated the 
effects of TPM on full-field electroretinography (ERG) and 
morphology of rabbits’ retina during a period of 8 months. 
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Full-field ERG revealed normal rod function in both case 
and control groups; however, a significant reduction in 30 Hz 
flicker b-wave amplitude was seen in the treated rabbits. His-
topathological investigation of the retinas revealed the cause 
of this deficit. The inner plexiform layer and amacrine cells 
in two-thirds of treated rabbits were extensively loaded with 
gamma-aminobutyric acid substance, a phenomenon similar 
to that seen in patients receiving vigabatrin (an antiepileptic 
drug). They proposed that such alterations having taken place 
within 8 months in rabbits would correspond to alterations 
occurring within a period of 20 years in humans treated 
with regular doses of TPM. On the contrary, Sills et al,27 in 
an experimental study, found that TPM was not appreciably 
concentrated in rats’ retina in spite of gabapentin.
In the present review, we found a 38-year-old female who 
had a previous history of vitelliform maculopathy. She had 
been taking TPM 400 mg/day for 4 years.72 This case can 
be introduced as a human instance of electronegative ERG 
following TPM therapy, and is in line with the findings of 
Kjellstrom et al.29
In another experimental study on rats,28 the effect of 
acute TPM use was investigated in two experiments. For 
the in vitro neurotoxicity experiment, researchers induced 
neurotoxicity in the retinal ganglion cells or retinal cells 
of rats. TPM was found to reduce neurotoxin-induced cell 
death in both groups of cells. For the in vivo retinal ischemia 
experiment, TPM was administered about 2 hours before 
and 5 minutes after increasing the IOP of the rats’ eyes to 
130 mmHg for 45 minutes. Histopathology of the retina 
(thickness of the inner plexiform layer) and ERG waves 
showed that TPM reduced retinal ischemic damage, and this 
effect was shown to be dependent on dosage.
Overall, although TPM has an acute neuroprotective 
effect in acute retinal ischemia and neurotoxicity, it may 
reduce retinal function when administered for long periods. 
However, further research seems to be necessary in order 
to clarify the long-term retinal effects of administration of 
this drug.
In 2004, a 32-year-old woman was reported with 
decreased visual acuity and defective color vision that was 
suspected to have been induced by the administration of 
400 mg/day TPM for 2 weeks. Further examination revealed 
that the patient had bilateral diffuse pigmentary retinopathy 
and maculopathy. Multifocal ERG showed bilateral depressed 
waveforms in the central area. TPM was discontinued 
without improvement in vision.45 In 2006, another case of 
bilateral maculopathy associated with central scotoma and 
reduced visual acuity (down to 6/10) was reported, in which 
symptoms occurred following 2 months of 150 mg/day TPM 
administration. Unfortunately, impaired visual conditions 
did not improve after 1 year of drug withdrawal.52 In a later 
report, a 41-year-old woman was described with decreased 
visual acuity and paracentral and arcuate scotoma OU. The 
patient had consumed 150 mg/day TPM for 41 months to 
prevent epilepsy. Her color vision was normal. Fluorescein 
angiography showed bilateral macular retinal pigment abnor-
malities presumed to be caused by TPM. She noted subjective 
improvement of her vision over the ensuing 6 months after 
drug withdrawal. However, fluorescein angiography and 
perimetry results remained unchanged.80
To date, TPM-induced retinal striae have been reported 
to occur simultaneously with myopia or TiACG in four 
cases.33,58,85,94 In almost all of these cases, retinal striae 
resolved well following drug discontinuation. Among them, 
there is an interesting case with retinal striae on the internal 
limiting membrane, without subfoveal fluid, that was detected 
by ocular coherence tomography.85 Guier58 postulated that 
retinal striae in ciliochoroidal effusion syndrome may be due 
to increased choroid thickness and a consequent decrease in 
the area of Bruch’s membrane/retinal pigmented epithelium 
complex that causes retinal redundancy and retinal striae.
In another report on two cases, authors attributed the 
evolution of rhegmatogenous retinal detachment to long-
term administration of TPM (in one case 18 months and 
in another case 12 months).75 In both cases, the presenting 
symptom was flashing. Also, one of the cases presented lattice 
degeneration. In response to this report, Natesh99 in a letter to 
the editor suspected the relation of TPM to rhegmatogenous 
retinal detachment and related the symptoms to posterior 
vitreous detachment. He emphasized that rhegmatogenous 
retinal detachment has a completely different mechanism 
from ciliochoroidal effusion syndrome.
Visual field defects
According to the original manufacturer’s report, visual field 
defects occurred in between 1:100 and 1:1000 cases during 
clinical trials for drug safety approval; however, the specific 
nature of these defects was not mentioned.39 It is worth noting 
that peripheral field losses are common in migraine patients 
and clinicians should differentiate such field losses from 
TPM-associated field defects.100
In 2003, the first case of TPM-induced visual field defect 
was documented by Foroozan and Buono.39 They described a 
32-year-old female with right-sided visual field defects who 
had been on oral 100 mg/day TPM for the past 6 weeks as 
a migraine prophylaxis. She had past history of craniotomy 
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due to generalized seizures and also a left temporal lobe 
arteriovenous malformation that was diagnosed at 6 years of 
age. Her ocular examinations were normal and visual acuity 
was 20/20 OU. Automated perimetry was performed and the 
patient was diagnosed with incongruous right homonymous 
hemianopia. TPM was discontinued and this resulted in 
resolution of the condition. Later, regarding this report, it was 
proposed that TPM might have further affected neurons 
already damaged at the site of the previous surgery, which 
in turn had resulted in visual field loss.
In another report in 2006,52 authors described a 16-year-
old girl who developed incongruent left hemianopia follow-
ing 3 months medication with TPM (125 mg/day). Ocular 
examinations were normal. TPM was withdrawn and conse-
quently her visual field partially improved. In 2008, two other 
cases of bilateral peripheral visual field defects were reported. 
These field defects recovered after cessation of TPM.71
TPM neuroophthalmologic manifestations
First and foremost, it is important to mention that Fraunfelder 
et al reported diplopia and nystagmusin in 14%–15% of cases 
taking high doses of TPM.23 Evans57 reported two cases of 
dose-related TPM-induced palinopsia. Both patients had been 
receiving the drug to control migraine. In these two cases, 
symptoms occurred 2.5 years and 1 month after administration 
of 200 mg/day and 75 mg/day of TPM, respectively. Frequency 
of symptoms was completely correlated to fluctuations 
in TPM dosage, with symptoms disappearing completely 
on discontinuation of the drug. Moreover, in this study, 
another case presenting with Alice in Wonderland syndrome 
was described with presentation of the symptom 1 week 
after administration of 100 mg/day TPM for the treatment 
of migraine. Although, this symptom disappeared after 
discontinuation of TPM, the author suspected an association 
between the syndrome and TPM; since the study lacked a 
rechallenge test. The author stated that it was not clear whether 
the symptom was related to TPM or migraine. Engagingly, 
such an association between TPM and Alice in Wonderland 
syndrome is also reported in another patient, a 17-year-
old female migraine sufferer. In this report, the index case 
had never complained of similar problems associated with 
migraine. When TPM dosage was increased to 75 mg/day, 
she complained of body distortion and when the dosage 
of TPM was decreased, the symptoms were completely 
resolved. Of note, in this case, a rechallenge test was 
carried out with positive results.95 In addition, in the present 
review, we found a patient with a personality disorder who 
presented with TPM-induced (100 mg/day) palinopsia.73
Probable corneal and scleral side effects
Concerning the effects of TPM on corneal thickness, 
the cardinal report on this subject was published by 
Kerimoglu et al.83 They presented a TiMS patient whose 
central corneal thickness had increased (OD: 543 µm, 
OS: 561 µm), as measured by Pentacam Scheimpflug 
imaging. TPM was suspected as being the cause, and so 
was withdrawn. Over the ensuing 3 weeks, the thickness 
of the patient’s cornea gradually decreased (OD: 528 µm, 
OS: 536 µm). The authors concluded that this effect may 
be attributed to the fact that TPM is a carbonic anhydrase 
inhibitor.
Ozturk et al,25 in their prospective study on the ocular 
side effects of TPM, reported possible changes in the mean 
central corneal thickness (from 570 µm at initiation to 
574 µm at the end of 3 months). However, the difference 
between these values was not of statistical significance.
As corneal thickness is of crucial importance in the 
field of keratorefractive surgery, further research should be 
carried out in this field.
Concerning the possible effects of TPM on the sclera, 
Fraunfelder et al reported on four patients with scleritis – one 
had bilateral and three had posterior involvement. Also, in 
the patient with bilateral scleritis, thickening of the sclera 
was observed.23
Other rare complications
In the literature, there are other scanty reports on rare 
p  ossible complications related to TPM medication. 
For example, Santmyire-Rosenberger and Albert50 
reported a case of trichomegaly in a 25-year-old bipolar 
patient who had been administered TPM 400 mg/day for 
4 months. Also, in   Fraunfelder et al’s report, two patients 
with   blepharospasm were presented, one of whom showed 
a positive rechallenge test.23 Moreover, other rare com-
plications might be myokymia, oculogyric crisis, and 
periorbital edema.23
TPM ophthalmologic applications
In comparison to the adverse ophthalmologic side effects 
of TPM, its beneficial applications in the field of clinical 
ophthalmology are scarce. However, two instances in the 
literature are worth considering. Recently, TPM has been 
reported to control chronic corneal pain in a case of post-
traumatic recurrent corneal erosions.30 Also, TPM was 
found to be an effective agent in reducing complex visual 
hallucinations in a 51-year-old woman following bilateral 
posterior cerebral artery infarction.31
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Recommendations
Regarding the aforementioned complications, ophthalmolo-
gists should consider IOP measurement, detailed fundus 
examinations, refraction tests, and visual field evaluations 
for patients referred with concurrent blurry vision and 
  history of TPM administration. It is important to note that 
TPM-induced symptoms might be confused with the visual 
aura and/or pain of a migraine attack. Such a   misdiagnosis 
can lead to a practitioner mistakenly increasing a patient’s 
dosage of TPM. Another important point is that TiACG 
attacks   commonly occur in the first 2 weeks after the 
initial administration or after a doubling of the dosage of 
the drug (Table 2). It is important for physicians to warn 
their patients about this issue during these critical periods. 
Despite the possible   idiosyncratic nature of TPM side 
effects, further prospective studies similar to those carried 
out by Ozturk et al25 and Leung et al26 but with a longer 
follow-up duration, are needed to elucidate dose-dependent 
ocular manifestations.
Due to the expanding spectrum of indications for 
  medication with TPM, neurologists and psychiatrists should 
be aware of the diverse ocular side effects of this drug. It is 
imperative that any visual complication be taken seriously 
and followed up by an ophthalmologist. Based on this review 
of the literature, the effects of TPM on vision are not only a 
simple category of side effects, but necessitate a joint effort 
on the part of practitioners and researchers to address an 
issue that spans three specialties of medicine, ie, neurology, 
psychiatry, and ophthalmology.
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